Cervicofacial actinomycosis is a bacterial infection managed with a combination of surgical and antibiotic strategies. The approach depends in part on the patient's allergy status. For patients with no penicillin allergy, a defined first-line regimen is recommended — distinct from the alternative used when penicillin cannot be given.
This protocol applies to patients presenting with cervicofacial actinomycosis who have no documented penicillin allergy. When a penicillin allergy is present, a different antibiotic class is substituted instead.
Management involves a surgical approach combined with intravenous antibiotic therapy until clinical improvement is achieved, followed by a course of oral antibiotics. The specific drug selection, dosing, and full sequence are detailed in the complete structured protocol.
The primary target is clinical improvement. Time to improvement varies across patients and is the key outcome tracked during treatment.
In case of penicillin allergy, clindamycin would be administered.
When actinomycosis is suspected, our review has shown that a surgical approach in combination with intravenous penicillin and metronidazol until clinical improvement is seen, followed by oral antibiotics for 2 – 4 weeks is generally efficient.
Sixteen (84.2%) patients were treated with intravenous antibiotics, incision and drainage of the swelling, and debridement of necrotic tissue, if needed.
Intravenous AB treatment most frequently (10 of 19; 52.6%) consisted of penicillin G 12 million units/day with metronidazol 500 mg 3/day.
All forms of actinomycosis are treated with high doses of intravenous penicillin G over two to six weeks, followed by oral penicillin V.
Patients were discharged from hospital when clinical improvement was seen.
Time to clinical improvement ranged from 1 to 46 days (SD 8.4 ± 13.2) when treated with intravenous AB.
View source ↗